This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 21 from Patent US 20060122119
General Information
DRACP ID DRACP01286
Peptide Name Sequence 21 from Patent US 20060122119
Sequence TTAEEAAGIGIL
Sequence Length 12
UniProt ID Q16655
PubChem CID Not available
Origin Homo sapiens
Type Native peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C49H84N12O19
Absent amino acids CDFHKMNPQRSVWY
Common amino acids A
Mass 134168
Pl 3.61
Basic residues 0
Acidic residues 2
Hydrophobic residues 6
Net charge -2
Boman Index 331
Hydrophobicity 75
Aliphatic Index 122.5
Half Life
Mammalian: 7.2 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2006/0122119 A1
Patent Title Peptides for use in antitumor immunotherapy.
Other Iinformation Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002
Other Published ID CA2477762A1 EP1481009A2 WO2003074565A2 WO2003074565A3
This work is licensed under a Creative Commons Attribution 4.0 International License.